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ScienceDirectPlant-based expression offers a safe, inexpensive and
potentially limitless way to produce therapeutics in a quick and
flexible manner. Plants require only simple inorganic nutrients,
water, carbon dioxide and sunlight for efficient growth. Virus-
like particles (VLPs) are convincing look-alikes of viruses but
without carrying infectious genomic material. However, they
can still elicit a very potent immune response which makes
them ideal vaccine candidates. In this review the different
methods of plant expression are described together with the
most recent developments in the field of transiently-expressed
plant-made VLPs.
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Introduction
Molecular pharming is a modern buzzword that refers to
the recombinant expression of pharmaceutically useful
proteins in plants. In recent years plants have become an
attractive tool for the production of a wide array of
pharmaceutical components as many researchers have
discovered the advantages of plants as bioreactors. One
of the reasons for the renewed interest in plants as
bioreactors is the development of methods for the rapid
production of candidate proteins via transient expression,
obviating the requirement for lengthy transformation and
regeneration procedures. This review will focus on the
use of transient expression to express viral coat proteins
that are able to assemble into virus-like particles (VLPs).
Virus-like particles and their power
A VLP is a version of a viral particle that mimics its
morphology but is lacking infectious genomic material.
However, VLPs retain the native antigenic conformation
of the immunogenic proteins and the repetitive structure
of the original virus particle. They thus combine both
safety and the potency to elicit a strong immune responsewww.sciencedirect.com [1,2] due to their size, shape and surface where they
display epitopes in a dense repetitive array [3,4]. Follow-
ing the expression of the viral proteins many self-assem-
ble spontaneously into VLPs, though some require a
maturation step. Currently used non-recombinant vac-
cines against viral diseases are made from lab-cultured
pathogens which have to be attenuated or inactivated.
This comes with bio-containment concerns because of
the risk of residual pathogenic activity due to incomplete
attenuation or inactivation. It is of fundamental impor-
tance for a vaccine to be unable to cause disease without
compromising immunogenicity. A potentially safer ap-
proach is therefore the synthesis of vaccines based on the
expression of specific components of pathogens which
can mimic the immunological properties of the original
virus without its pathogenic properties and VLPs are
excellent candidates for such synthetic vaccines. In addi-
tion, certain VLPs have also been investigated as poten-
tial drug-delivery vehicles and as imaging agents for
biomedical purposes.
Plants are the expression hosts of the future
In the last 20 years plants have become serious compe-
titors to other production systems for pharmaceuticals,
such as bacteria, yeast or mammalian cells. They are
robust, inexpensive to grow and bring a low risk of
contamination with endotoxins or mammalian pathogens
[5–7], which can be an issue with mammalian cell cul-
tures. Unlike prokaryotic expression systems, plants are
able to introduce post-translational modifications such as
glycosylation [8]. In insect and yeast cells glycosylation is
limited to very simple and inconsistent high mannose
glycoforms [4]. Any production system for pharmaceutical
components, especially vaccines, has to be quick in the
response to a sudden increase in demand. Transient
expression in plants can be adjusted rapidly with low
manufacturing costs [6,9].
Nicotiana benthamiana has long been the favourite host
when it comes to the production of recombinant proteins
since it is well studied and agro-infiltration is easy without
causing great damage to the tissue [10]. Additionally, it
allows a wide range of plant viruses to replicate which
makes it a versatile host for virus-derived expression
vectors. However, protein production in plants is not
limited to N. benthamiana. Several types of plants and
plant tissues have been used for the production of pro-
teins including potato, alfalfa and Arabidopsis thaliana;
however, lettuce stands out as a production host that
combines all the benefits from N. benthamiana but con-
tains fewer phenolics and alkaloids which can be difficult
to remove [11–13]. A decade or two ago the idea of edibleCurrent Opinion in Biotechnology 2016, 37:201–206
202 Plant biotechnologyvaccines, in which plant tissue expressing the recombi-
nant protein would be directly consumed, sparked a lot of
interest but has now lost its popularity due to problems of
dose and quality control which is difficult to guarantee
without purification [14,15].
Stable-expression versus transient-
expression
There are two different ways to express pharmaceuticals,
including VLPs, in plants: stable transformation of either
the nuclear or plasmid genome or transient expression.
Though used for seminal studies in the early days of
molecular pharming, the use of stable transformation has
declined as the process is time-consuming and therefore
not suitable for rapid screening of a wide variety of
different constructs or a quick response to emerging
epidemics [16]. Transient expression uses the soil bacte-
rium, Agrobacterium tumefaciens, which in nature causes
crown gall disease, to deliver foreign sequences to plants
(Figure 1). Since the 1970s it has been known that this
gram-negative bacterium can transfer a part of its special
Ti (tumor-inducing) plasmid into the plant cell where it
then integrates into the host genome [17]. The gene of
interest is inserted into the T-DNA region of a binary
plasmid which will then be expressed in the plant cell.
This allows screening and production in a matter of days.
However expression is limited to the infiltrated tissue but
large-scale production and processing has been devel-
oped [18]. This is in contrast to stable transformation
where the foreign gene becomes part of the genome and
making the transgene heritable through succeeding gen-
erations.
Viral vectors used for VLP production
A number of plant viruses have been employed for
transient expression of VLPs. These range from vectorsFigure 1
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Current Opinion in Biotechnology 2016, 37:201–206 based on the complete viral genome to which a foreign
gene has been added, through deconstructed vectors in
which non-essential viral functions have been deleted, to
non-replicating virus-based systems. Full viral vectors
behave like a wild type virus by moving within their host
and producing infectious virus particles but are also able
to express heterologous proteins. Their ability to replicate
and move both from cell to cell and systemically results in
extremely high levels of protein expression. However,
during replication the gene insert can undergo mutation
or deletion and it is difficult to express several genes in
the same cell. Two full virus vectors, based on potato
virus X (PVX) and cowpea mosaic virus (CPMV), though
mostly used for epitope display [19,20], have also been
used for the plant-based expression of hepatitis B core-
like particles [21]. The use of full virus vectors has been
reviewed by Porta and Lomonossoff [22,23].
The creation of deconstructed viral vectors involves the
removal of viral genes which are not essential for the
production of the target protein, for example the viral coat
protein, and may be replication-competent or replication-
deficient. They are designed for rapid, high level produc-
tion of recombinant proteins in plants, without the
problems of biocontainment. The history and use of
deconstructed viral vectors has recently been reviewed
[24] and the pEAQ and magnICON1-systems have, in
particular, been used to produce VLPs in plants [25].
Transiently-expressed VLPs
Hepatitis B virus core-like particles (CLPs)
Hepatitis B CLPs were one of the first particles to be
produced by transient expression in plants [21]. Expres-
sion of a monomeric form of the core antigen HBcAg
results in the spontaneous formation of CLPs in several
heterologous systems, including plants. Multiple studies in plants
ays
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Examples of VLPs transiently expressed in plants, visualized using transmission electron microscopy on negatively-stained samples. (a) Tandem
core HBcAg particle with anti-GFP nanobody fused to e1 loop and bound GFP, (b) BTV VLPs, (c) CPMV eVLPs.have shown that HBc particles have a strong inherent
immunogenicity due to their spiky structure and repeti-
tive presentation of antigenic determinants on their sur-
face [26,27], and such particles can be used for the
display of foreign peptides. Peyret et al. [26] reported
the development of a generic carrier system for antigens
of interest using HBcAg dimers produced by the tandem
fusion of two HBcAg open reading frames; these retain
their ability to self-assemble into CLPs. This so-called
‘tandem core’ system allows the modification of only one
of each pair of immunodominant e1 loops which form the
spikes on the surface of the particle, thereby permitting
the display of larger inserts than is possible with the
monomeric core protein [27]. Peyret et al. showed that
tandem core particles can be used to display correctly
folded GFP or camelid nanobodies. The latter application
results in the creation of structures termed ‘tandibodies’
that retain the ability of the nanobody to bind its cognate
antigen [26] (Figures 2a and 3).Figure 3
Cryo-EM reconstruction of plant-produced tandem core HBcAg particle wit
from Peyret et al. [26]).
www.sciencedirect.com Papillomaviruses
Papillomaviruses (PVs) are non-enveloped tumor-induc-
ing DNA viruses comprising a large family of more than
100 species that mostly infect humans. Human PV (HPV)
accounts for approximately 5% of all human cancers
[28,29]. HPV-5 and HPV-8 are high-risk cutaneous HPVs
(cHPVs), which were the first HPVs suspected of human
tumorigenesis [30]. Their capsid is about 55 nm in diam-
eter formed by the major (L1) and minor (L2) capsid
protein. The L1 protein self-assembles into highly im-
munogenic VLPs or into capsomers made of five L1
monomers [31]. Two types of HPV VLP vaccines are
currently on the market based on L1 expressed in insect
or yeast cells. Even though they are very efficient, they
suffer from high production costs and relatively low
protection levels [14]. For that reason Matic´ et al. aimed
to develop an alternative vaccine made in plants [25].
They expressed full-length HPV-8 L1 and a truncated
version, produced by deleting the C-terminal nuclearCurrent Opinion in Biotechnology
h anti-GFP nanobody fused to e1 loop and bound GFP (Reproduced
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vectors. Overall pEAQ-HT induced the highest expres-
sion of HPV-8 L1 proteins and electron microscopy
proved that assembly of the expressed HPV-8 L1 into
VLPs of T = 1 or T = 7 symmetry had occurred [25].
Bovine papillomavirus (BPV) is endemic throughout the
world and causes a variety of economically important
tumorigenic pathologies in horses and cattle [32]. Struc-
turally and genetically they resemble HPV. Love et al.
[32] aimed to produce a plant-expressed candidate vac-
cine against BPV-1. They succeeded in expressing the L1
major capsid with pEAQ-HT in N. benthaminana which
self-assembled into T = 1 VLPs with 30 nm in diameter.
These VLPs gave a positive immune response in rabbits
and therefore represent the first example of the produc-
tion of a feasible BPV vaccine in plants [32].
Bluetongue virus
Bluetongue virus (BTV) is a non-enveloped virus infect-
ing ruminants causing the Bluetongue Disease which is
insect-transmitted. It has a multicomponent double
stranded RNA genome encapsidated in a complex virion.
There are more than 26 known serotypes of the virus and
their virulence and mortality rate vary considerably,
depending also on the infected species [33]. Its multi-
layered capsid is built out of four structural proteins
arranged in three concentric shells; each protein is present
in a different stoichiometry. Despite this complex setup,
BTV VLPs have previously been expressed in insect cells
[34,35] and have now also been produced in plants using
pEAQ-HT [36] (Figure 2b). The approach to their
production involved the co-expression of the four differ-
ent viral structural proteins with carefully adjusted ratios
in order to obtain large quantities of correctly-assembled
VLPs. These BTV-8 VLPs proved to be effective at
protecting sheep from challenge [36].
Norovirus
Norwalk virus (NV) is the prototype of human noro-
viruses and causes acute gastroenteritis in humans. The
capsids consist of 180 copies of single protein of 58 kDa
which self-assemble into 38 nm diameter empty capsids
when expressed in insect cells [37]. The major problem
for developing a viable vaccine against NV is that there is
currently no method of propagating the virus in cell
culture and hence traditional killed or live-attenuated
vaccines have not been developed. NV VLPs were first
transiently expressed in plants in the 1990s [38] and since
then in several transgenic plant species [38,39]. Research
has most recently focused on the transient expression of
the Narita 104 virus capsid protein (NaVCP) in Nicotiana
benthamiana using the magnICON1 system [40,41].
Mathew et al. confirmed the production of NaVCP VLPs
which generate a significant mucosal and serum antibody
response when inoculated into mice demonstrating thatCurrent Opinion in Biotechnology 2016, 37:201–206 the authors had made a potential plant-derived vaccine
candidate against NV [40].
Influenza virus
Influenza virus is a major threat to human populations
worldwide. Current vaccines are based on the surface
proteins hemagglutinin (HA) and neuraminidase (NA)
both of which are highly variable making it difficult to
develop broad-range vaccines. New strains rapidly
emerge every year, which can cause pandemics, which,
in turn, demands a faster way of vaccine production than
is currently possible using embryonated eggs. D’Aoust
et al. showed that plants are capable of producing envel-
oped influenza VLPs containing HA which elicit a pro-
tective immune response in mice [42,43]. Recently
Medicago USA Inc. adapted the plant-based influenza
VLP expression to large-scale production allowing the
purified end product to be obtained only 3 weeks after
receiving the HA sequence [18]. Currently Medicago are
conducting phase II clinical trial with their avian flu H5
pandemic vaccine candidate and have reported that the
candidate vaccine was found to be safe and well tolerated.
They have also reported positive results from a US Phase
I human clinical trial with its seasonal influenza vaccine
candidate (www.medigaco.com).
Cowpea mosaic virus
The aim of producing VLPs based on CPMV was to make
RNA-free empty VLPs (eVLPs) for use in bionanotech-
nology rather than producing a candidate vaccine
(Figure 2c). Such eVLPs were generated by the transient
co-expression of the precursor of the two viral coat pro-
teins, VP60, and the viral proteinase, 24K in N. benthami-
ana using the pEAQ-HT expression system [44]. By
optimising the infiltration and purification procedures,
the yield of eVLPs could reach levels comparable with
the levels of native particles achieved via infection [45].
The eVLPs thus produced are being developed for vari-
ous applications in bio-nanotechnology, including mag-
netic hyperthermia, epitope display and cell-specific
targeting of drugs [46,47]. The recent atomic resolution
cryo-electron microscope structure of CPMV eVLPs and
comparison with the native virus structure [48] confirms
the authenticity of VLPs produced by transient expres-
sion in plants and should aid the development of applica-
tions for such VLPs.
Conclusions
Plant molecular pharming, the production of pharmaceu-
ticals in plants is a promising technology with increasing
interest for vaccine development. Evidence and proof of
principle are summarized in this review. It has been
shown that a wide variety of VLPs can routinely be
produced in plants and success in generating a protective
immune response in animal models has been reported.
Plants are an economical and safe platform for vaccine
development due to ease in scalability and a low risk ofwww.sciencedirect.com
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Hence we can expect this production system to persuade
the sceptics and become approved for the use of emer-
gency response therapeutics and vaccines in humans.
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